The phase III, randomized, double-blind, placebo-controlled KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma

S. Y. Rha, A. Kawazoe, Y. Bai, J. Xu, S. Lonardi,J-P. Metges,P. E. Yanez Weber, L. S. Wyrwicz, L. Shen, Y. V. Ostapenko, M. Bilici, H. C. Chung, K. Shitara, S. Qin,E. van Cutsem, J. Tabernero,K. Li,C-S. Shih, P. Bhagia, Y. Y. Janjigian

ANNALS OF ONCOLOGY（2023）

引用 0|浏览1